Insight Molecular Diagnostics Inc. (IMDX)
IMDX moved a median of 0.00% 30 minutes after news, and +0.45% by the close. How IMDX actually reacts to news — the realized, point-in-time move the market made, measured across 81 labeled events over the last three years with zero look-ahead.
IMDX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.21% | 27% | 75 |
| 30-min | 0.00% | 47% | 76 |
| 60-min | 0.00% | 51% | 79 |
| to close | +0.45% | 52% | 75 |
| Middle 50% of IMDX reactions | -1.04% to +3.10% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 81 |
Half of all Insight Molecular Diagnostics Inc. news events land between -1.04% and +3.10% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when IMDX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to IMDX's baseline. Nothing else.
Recent IMDX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| iMDx Welcomes New Diagnostics Sales Leader to Prepare for Planned GraftAssureDx Launch | Press release | GlobeNewswire | -2.01% | -6.38% | |
| iMDx to Participate in Virtual U.S. Bancorp I BTIG Kidney Health Forum with KOL Discussion and Investor Meetings | Press release | GlobeNewswire | -4.30% | -5.37% | |
| Form 8-K Insight Molecular Diagno For: Sep 15 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.48% | |
| iMDx to Participate in Lake Street 10th Annual Best Ideas Growth “BIG10” Conference | Press release | GlobeNewswire | +0.00% | +5.25% | |
| Insight Molecular Diagnostics to Host Virtual KOL Event on August 17, 2026: Moving Toward In-House Heart Transplanted Organ Rejection Testing | Press release | GlobeNewswire | +0.00% | +0.45% | |
| iMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 Conference | Press release | GlobeNewswire | +1.76% | +0.20% | |
| Form S-8 Insight Molecular Diagno | SEC filing · Form S-8 | SEC EDGAR | -0.83% | -2.08% | |
| iMDx GraftAssure Assay Guides Use of Potentially Kidney-Graft-Saving Drug in New Lancet Group Publication | Press release | GlobeNewswire | +1.85% | +2.06% | |
| Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio | Press release | GlobeNewswire | -0.86% | +1.07% | |
| IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper | Press release | GlobeNewswire | -0.36% | -1.46% | |
| iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant | Press release | GlobeNewswire | +0.38% | +3.25% | |
| Form 8-K Insight Molecular Diagno For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +1.11% | |
| Favorable Head-to-Head Data on iMDx’s GraftAssure with Competing NGS Assay Published in Clinical Chemistry | Press release | GlobeNewswire | +1.30% | -1.11% | |
| IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation | Press release | GlobeNewswire | +2.55% | +3.13% | |
| iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress | Press release | GlobeNewswire | +0.87% | +0.52% | |
| Form 10-Q Insight Molecular Diagno For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +8.74% | +30.49% | |
| Form 8-K Insight Molecular Diagno For: May 13 | SEC filing · Form 8-K | SEC EDGAR | +8.74% | +30.49% | |
| Form 8-K/A Insight Molecular Diagno For: Feb 20 | SEC filing · Form 8-K | SEC EDGAR | +8.74% | +30.49% | |
| IMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization | Press release | GlobeNewswire | +8.74% | +30.49% | |
| iMDx to Release First Quarter 2026 Results on May 13, 2026 | Press release | GlobeNewswire | +1.40% | -1.00% | |
| Form 8-K Insight Molecular Diagno For: Apr 30 | SEC filing · Form 8-K | SEC EDGAR | -3.38% | +4.50% | |
| Form ARS Insight Molecular Diagno For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -3.38% | +4.50% | |
| Form DEF 14A Insight Molecular Diagno For: Apr 30 | SEC filing · Form DEF | SEC EDGAR | -3.38% | +4.50% | |
| Form DEFA14A Insight Molecular Diagno | SEC filing · Form DEFA14A | SEC EDGAR | -3.38% | +4.50% | |
| Real-World Evidence and Industry Momentum Builds for iMDx’s Flagship GraftAssure Assay | Press release | GlobeNewswire | +0.00% | +18.36% | |
| Form 10-K Insight Molecular Diagno For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -3.96% | -14.63% | |
| Form 8-K Insight Molecular Diagno For: Mar 26 | SEC filing · Form 8-K | SEC EDGAR | -3.96% | -14.63% | |
| IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results | Press release | GlobeNewswire | -3.96% | -14.63% | |
| iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare Conference | Press release | GlobeNewswire | +0.00% | +4.93% | |
| Second Study Affirms Superiority of iMDx GraftAssure Assay’s Proprietary dd-cfDNA Combination Model Score | Press release | GlobeNewswire | — | -0.81% | |
| Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission | Press release | GlobeNewswire | +7.20% | +4.61% | |
| Form 8-K Insight Molecular Diagno For: Feb 20 | SEC filing · Form 8-K | SEC EDGAR | -0.17% | +5.07% | |
| Form 8-K Insight Molecular Diagno For: Feb 10 | SEC filing · Form 8-K | SEC EDGAR | -2.01% | -6.86% | |
| Form 8-K Insight Molecular Diagno For: Feb 11 | SEC filing · Form 8-K | SEC EDGAR | -7.38% | -10.05% | |
| iMDx Announces $26.0 Million Registered Direct Offering | Press release | GlobeNewswire | -7.38% | -10.05% | |
| IMDX Supports AST and ASHI STAR Working Group’s Call for Decentralized Transplant Monitoring | Press release | GlobeNewswire | +0.00% | +1.83% | |
| iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation | Press release | GlobeNewswire | +0.00% | +0.00% | |
| iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch | Press release | GlobeNewswire | -0.14% | -0.27% | |
| iMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion | Press release | GlobeNewswire | +0.00% | +4.62% | |
| Form 10-Q Insight Molecular Diagno For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.26% | +13.16% | |
| Form 8-K Insight Molecular Diagno For: Nov 10 | SEC filing · Form 8-K | SEC EDGAR | -2.26% | +13.16% | |
| IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launch | Press release | GlobeNewswire | -2.26% | +13.16% | |
| iMDx to Release Third Quarter 2025 Results on November 10 and Attend Stephens Annual Investment Conference the Following Week | Press release | GlobeNewswire | -5.69% | -0.33% | |
| iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch | Press release | GlobeNewswire | +1.55% | +5.16% | |
| iMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset’ with Novel Therapy and GraftAssure Monitoring | Press release | GlobeNewswire | -5.08% | -9.89% | |
| Form 8-K Insight Molecular Diagno For: Sep 28 | SEC filing · Form 8-K | SEC EDGAR | +2.46% | +0.90% | |
| Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando | Press release | GlobeNewswire | +0.00% | +5.30% | |
| Form 8-K Insight Molecular Diagno For: Sep 16 | SEC filing · Form 8-K | SEC EDGAR | -0.59% | -4.11% | |
| IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants | Press release | GlobeNewswire | +1.80% | -0.40% | |
| Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database | Press release | GlobeNewswire | +1.80% | -0.40% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the IMDX section they belong to.
Where else IMDX is measured.
IMDX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Insight Molecular Diagnostics Inc.'s median reaction calculated?
Every labeled IMDX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 81 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 47% of IMDX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does IMDX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.